# US 2026/0076979 A1 · Composition for the treatment of covid-19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076979 A1
- Document ID: US20260076979A1
- Status: Published application
- Kind: A1
- Application number: 18/890,710
- Filed: 2024-09-19
- Published: 2026-03-19
- Earliest claimed: 2024-09-19
- Inventors: Albert Nguyen
- Web page: https://patentgrep.com/patent/US20260076979A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

## Claims

### Claim 1

A composition for the treatment of COVID-19, comprising:
an effective amount a first compound, the first compound comprising an effective amount of dexamethasone comprising approximately 10 mg of dexamethasone; and
an effective amount of a second compound, the second compound comprising an effective amount of triamcinolone acetonide comprising approximately 40 mg to 80 mg of triamcinolone acetonide,
wherein the effective amount of dexamethasone and the effective amount of triamcinolone acetonide are administered via injection once per day.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the second compound further comprises effective amounts of sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the second compound further comprises hydrochloric acid.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the effective amount of sodium chloride is 0.66%.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the effective amount of benzyl alcohol is 0.99% (w/v).

### Claim 6 (depends on 5)

The composition of claim 5, wherein the effective amount of carboxymethylcellulose sodium is 0.63%.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the effective amount of polysorbate 80 is 0.04%.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the pH of the second compound is between approximately 5.0 and approximately 7.5.

### Claim 9 (depends on 2)

The composition of claim 2, wherein an effective amount of the composition for the treatment of the patient having mild symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
48 mg of triamcinolone.

### Claim 10 (depends on 2)

The composition of claim 2, wherein an effective amount of the composition for the treatment of the patient having moderate symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
60 mg of triamcinolone.

### Claim 11 (depends on 2)

The composition of claim 2, wherein an effective amount of the composition for the treatment of the patient having severe symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
80 mg of triamcinolone.

### Claim 12

A method for the treatment of COVID-19, the method comprising the steps of:
forming a first composition, comprising:
approximately 10 mg of dexamethasone; and forming a second composition comprising approximately 48 mg to approximately 80 mg of the following:
approximately 48 mg to approximately 80 mg of triamcinolone acetonide;
sodium chloride;
benzyl alcohol;
carboxymethylcellulose sodium; and
polysorbate 80;
drawing the first composition into a 3 ml syringe;
drawing the second composition into the 3 ml syringe; and
injecting the combined composition from the syringe into a patient.

### Claim 13 (depends on 8)

The method of claim 8, wherein the second composition further comprises sodium hydroxide.

### Claim 14 (depends on 8)

The method of claim 8, wherein the second composition further comprises hydrochloric acid.

### Claim 15 (depends on 8)

The method of claim 8, wherein the pH of the second composition is between approximately 5.0 and approximately 7.5.

### Claim 16 (depends on 8)

The method of claim 8, wherein an effective amount of the composition for the treatment of the patient having mild symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
48 mg of triamcinolone,
wherein the effective amount of the combined composition is administered once per day; and once every subsequent two days until symptomatic resolution.

### Claim 17 (depends on 8)

The method of claim 8, wherein an effective amount of the composition for the treatment of the patient having moderate symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
60 mg of triamcinolone, wherein the effective amount of the combined composition is administered once per day; and once every subsequent two days until symptomatic resolution.

### Claim 18 (depends on 8)

The method of claim 8, wherein an effective amount of the composition for the treatment of the patient having severe symptoms of COVID-19 infection comprises:
10 mg of dexamethasone; and
80 mg of triamcinolone, wherein the effective amount of the combined composition is administered once per day; and once every subsequent day until symptomatic resolution.

### Claim 19 (depends on 12)

The method of claim 12, wherein the second compound is comprised of:
0.66% sodium chloride;
0.99% benzyl alcohol;
0.63% carboxymethylcellulose sodium; and
0.04% polysorbate 80.
